Compared with conventional imaging alone, patient-reported outcomes (PROs) integrated with machine learning may provide an earlier indication of breast cancer recurrence, disease progression, and survival.

A simplified, no-cost machine learning version of the Martin-Hopkins equation matched the original's accuracy across millions of blood samples, helping clinicians identify patients who qualify for lipid-lowering therapy.

Get engaged or get left out.

In an interview with Pharmacy Times, Nicole McMullin, regional clinical pharmacist at American Oncology Network, discussed AON’s development of an all-outpatient approach to step-up dosing for bispecific T-cell engager therapy in multiple myeloma.

An expert discusses a JAMA study that shows who depends on the MMRV combo shot and how policy shifts may widen gaps—plus how pharmacists keep kids on schedule.

In an interview with Pharmacy Times, Manale Maksour, PharmD, BCOP, BCPS, associate director of Pharmacy Services at American Oncology Network, discussed the growing use of outpatient step-up dosing for bispecific T-cell engager therapies and the operational challenges clinics must address to safely implement these programs.